Patent Application: Compositions and Methods for Reducing RNA Levels

The USPTO has published a new patent application (US20260085311A1) detailing compositions and methods for reducing RNA levels and treating diseases caused by toxic gain-of-function proteins. The application was filed on June 20, 2023.

Composition for Regulating Interfering Ribonucleic Acid Production

The USPTO has published a new patent application (US20260085312A1) detailing compositions and methods for regulating interfering ribonucleic acid (miRNA) production. The application describes techniques to decrease the bioavailability of target biomolecules by degrading or inactivating their corresponding messenger RNA (mRNA).

USPTO Patent Application for Modulating SMN2 RNA and Protein

The USPTO has published a patent application (US20260085313A1) detailing compounds, methods, and pharmaceutical compositions for modulating SMN2 RNA and protein. This application, filed on May 2, 2025, aims to ameliorate symptoms of neurodegenerative disorders.

Conjugated Oligonucleotide Compounds for Therapeutic Use

The USPTO has published a new patent application (US20260085314A1) for conjugated oligonucleotide compounds, methods of making them, and their therapeutic uses. The application was filed on May 16, 2025, by inventors Ahmad Ali Mortazavi, Viviana Mannella, and Muthusamy Jayaraman.

HMBOX1 Inhibitor for Muscle Atrophy Treatment

The USPTO has published a patent application (US20260085316A1) from Shanghai University detailing the use of a homeobox containing 1 (HMBOX1) inhibitor for the prevention and treatment of muscle atrophy. The application outlines findings from cellular and animal studies supporting the therapeutic potential of inhibiting HMBOX1 expression.

siRNA for AGT gene expression inhibition in hypertension treatment

The USPTO has published a new patent application (US20260085317A1) detailing modified oligonucleotide sequences designed as siRNAs to inhibit angiotensinogen (AGT) gene expression. The application suggests these siRNAs may be used in the development of treatments for hypertension and related diseases.

Patent Application: Cancer Treatment with Stat3 Decoy

The USPTO has published a new patent application (US20260085318A1) detailing methods for treating cancer using a STAT3 double-stranded, cyclic oligonucleotide decoy in combination with an immune checkpoint inhibitor. The application was filed on September 20, 2023, by inventors Daniel E. Johnson and Jennifer R. Grandis.

Engineered Polynucleotide for Cancer Treatment

The USPTO has published a patent application detailing an engineered polynucleotide designed to treat cancer by regulating gene expression. The application, filed on July 17, 2025, describes compositions and methods involving polynucleotides that interact with pre-mRNA and spliceosomes.

Millennium Energy Gas Cost Recovery Rate Report Approval

The Kentucky Public Service Commission approved Millennium Energy's Gas Cost Recovery (GCR) rate report, setting a new GCR rate of $2.6431 per Mcf, effective April 1, 2026. This represents a decrease of $0.7842 per Mcf from the previous rate. Millennium is also required to submit invoices and usage reports with future GCR filings.

Informal Conference on Gas Cost Recovery Rate Filing

The Kentucky Public Service Commission Staff has scheduled an informal conference to discuss issues related to the calculation methodology of the Gas Cost Recovery rate filing for Western Lewis-Rectorville Water and Gas District. The conference will address natural gas purchase and sale volumes and calculation methods.

Martin Gas Inc. GCR Rate Report Approval

The Kentucky Public Service Commission has approved Martin Gas Inc.'s proposed Gas Cost Recovery (GCR) rate report, effective April 1, 2026. The approved GCR rate is $6.5621 per Mcf, an increase of $0.1622 per Mcf from the previous rate. Martin Gas is also required to submit invoices and usage reports with future GCR filings.

PSC Investigates Water District Board Vacancy

The Kentucky Public Service Commission has opened an investigation into the North McLean County Water District's board of commissioners. The investigation will determine if a vacancy exists due to a commissioner allegedly failing to complete mandatory training within the required timeframe, as stipulated by state law.

Graves County Water District Joint Motion to Continue Stay

The Kentucky Public Service Commission has received a joint motion from Graves County Water District and Milburn Water District to continue an existing stay of proceedings until June 30, 2027. This motion follows previous orders granting stays to allow for the development of a comprehensive water supply plan for Carlisle County.

EU Initiates Trade Investigation into Grain-Oriented Steel

The European Commission has initiated an initial investigation (SAFE011) into grain-oriented flat-rolled products of silicon-electrical steel. The investigation covers all countries ('Erga Omnes') and aims to determine if these products are being dumped or subsidized, potentially leading to provisional or definitive measures.

EU Investigates Chinese Aluminium Extrusions - Expiry Review

The European Commission has initiated an expiry review investigation into Chinese aluminium extrusions under case R850. The investigation aims to determine if existing anti-dumping measures should be maintained or amended. Interested parties have until October 30, 2026, to submit comments on the final disclosure.

BIS Markets Committee Chair Term Extended

The Bank for International Settlements (BIS) announced that John C. Williams will continue as Chair of the BIS Markets Committee for a second three-year term. Mr. Williams, who also serves as President and CEO of the Federal Reserve Bank of New York, was first appointed to this role in January 2023.

FT SkyBridge Bitcoin Plus ETF Listing Proposal

NYSE Arca has filed a proposal to list and trade shares of the FT SkyBridge Bitcoin Plus ETF. This filing is a notice of proposed change under the Securities Exchange Act of 1934, initiating a review period for the listing of this new security-based swap. The filing includes contact information for NYSE staff and details regarding the submission process.

National Debt Interest to Consume 1 in 4 Tax Dollars by 2036

A Tax Foundation analysis projects that by 2036, interest payments on the national debt will consume one in four federal tax dollars. This analysis highlights the growing fiscal challenge posed by the national debt and its impact on federal spending priorities.

ECB Consumer Expectations Survey Results - February 2026

The ECB's Consumer Expectations Survey for February 2026 shows unchanged median perceptions of past inflation, but slight decreases in expectations for the next 12 months and three years ahead. Economic growth expectations improved, while spending growth expectations increased.

WA DOH Revokes, Suspends Health Care Provider Licenses

The Washington State Department of Health has indefinitely suspended the credentials of two health care providers, Reshawn Bernard Hayes and Hinda Ahmed Mohamed, in March 2026. These actions follow arrests, guilty pleas to domestic violence offenses, and alleged financial misconduct.

Washington State Disciplines Health Care Providers

The Washington State Department of Health has taken disciplinary actions against several health care providers in March 2026. Actions include charges of unprofessional conduct, denial of applications, and termination of probation, impacting providers across various counties.

US patent application for wearable mental disorder diagnosis system

US patent application for wearable mental disorder diagnosis system

Patent Application: Cognitive Load Adaptation in Mobile AI

The USPTO has published a patent application from International Business Machines Corporation for a system that adapts mobile AI content generation based on a user's cognitive load. The application, filed on September 23, 2024, aims to ensure generated content keeps the user's cognitive load within a desired threshold.

Patent Application: Monitoring User Emotional States from Devices

The USPTO has published a patent application (US20260083370A1) detailing methods for monitoring, tracking, and reporting user emotional states from a managed device. The application describes systems that analyze communication and operational data to determine emotional patterns and transmit reports to a managing device, potentially triggering alerts for negative emotional states.

Patent Application: Bifidobacterium longum for Infant Infection Prevention

The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.

GABA-producing bacteria for improving health patent application

The USPTO has published a new patent application (US20260083786A1) detailing a composition comprising Lactobacillus brevis (NCIMB 41903) for use in regulating or treating metabolic diseases. The application was filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton.

Formulation for Hair Growth

The USPTO has published a new patent application, US20260083789A1, for a formulation designed to stimulate hair growth and improve hair quality. The formulation primarily utilizes a nitrate-enriched extract of Amaranth, along with other plant-based ingredients. The application details the method of preparation and its potential use in enhancing hair growth rate, count, and density.

Patent Application: Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083791A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety, food cravings, and stress, and improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Cravings

The USPTO has published a new patent application (US20260083792A1) for methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, food cravings, and improve mood and overall health. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application: Dichrostachys glomerata for Anxiety and Stress Reduction

The USPTO has published a patent application (US20260083793A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083794A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety and improving mood. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Stress

The USPTO has published a new patent application (US20260083796A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and overall health in mammals. The application was filed on September 26, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Improve Mood

The USPTO has published a patent application (US20260083797A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, and stress, and to improve mood, energy, and overall health in mammals. The application was filed on September 26, 2024.

US Patent Application for Heart Boosting Formulation

The USPTO has published a new patent application (US20260083806A1) for a heart boosting formulation. The application details a specific composition including L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon, and beetroot, along with related manufacturing methods. The filing date was September 16, 2025.

Antiviral Fungal Extracts Prevent Coronavirus Infections

The USPTO has published a patent application (US20260083788A1) detailing antiviral fungal extracts that may prevent coronavirus infections by interfering with the Spike protein. The application, filed by Mycotech Pharma AS, describes compositions derived from Agaricus blazei, Grifola frondosa, and Hericium erinaceus.

Patent Application: Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083809A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Reducing Visceral Fat Using Plants and Spices

The USPTO has published a new patent application (US20260083810A1) detailing methods and compositions for reducing visceral fat in mammals using plants and spices such as Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is scheduled for publication on March 26, 2026.

Patent Application: Reducing Blood Lipids Using Plants

The USPTO has published a patent application (US20260083811A1) detailing methods and compositions for reducing blood lipids using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes compositions aimed at increasing GLP-1 levels and reducing visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

Patent Application: Reducing Fasting Blood Glucose Using Plants

The USPTO has published a new patent application detailing methods and compositions for reducing fasting blood glucose using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes oral dosage forms for health benefits including increased GLP-1 levels and reduced blood lipids.

Patent Application for Reducing DPP-4 Activity with Plants

The USPTO has published a new patent application (US20260083813A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce DPP-4 activity or levels in mammals. The application was filed on September 26, 2024.

USPTO Patent Application for Dietary Supplement Formulation

The USPTO has published a patent application (US20260083814A1) for a dietary supplement formulation designed to alleviate sciatica pain and support nerve and musculoskeletal health. The application details a specific blend of natural ingredients and their purported benefits, filed on September 26, 2024.

Patent Application for Cancer Treatment Combination Therapies

The USPTO has published a new patent application (US20260083816A1) detailing methods for treating cancer using combination therapies. The application, filed by inventors Erlinda M. Gordon and Fredrick L. Hall, focuses on inhibiting cyclin proteins and targeting pathways that promote cyclin activity.

FDA Acknowledgment Letter to Ingram Planetarium

The Food and Drug Administration (FDA) has issued an acknowledgment letter to Ingram Planetarium regarding a submission. The letter, dated March 26, 2026, confirms receipt of documentation from the Center for Devices and Radiological Health (CDRH). No specific details about the submission's content or regulatory implications are provided.

FDA Variance Application from Axion Laser

The Food and Drug Administration (FDA) has posted a variance application from Axion Laser. This document is available for review on the FDA's regulations.gov portal.

FDA Variance Approval Letter to DePaul University

The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to DePaul University's Idea Realization Laboratory. This document signifies approval for a specific variance related to medical device development or testing.

FDA Completeness Assessment Correspondence

The Food and Drug Administration (FDA) has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that documentation is available for review via the provided URL, though no specific documents are directly viewable or downloadable from the initial posting.

FDA Complaint Document - Closed for Comments

The Food and Drug Administration (FDA) has opened a public comment period for a new complaint document, identified by docket number FDA-2026-H-2944. The comment period is scheduled to close on March 26th.

FDA Complaint Document Details

The Food and Drug Administration (FDA) has posted details regarding a complaint document, with the information made available on March 26, 2026. The document is related to the Center for Tobacco Products (CTP) and is available for download.

FDA Variance Amendment from DePaul University Idea Realization Laboratory

The Food and Drug Administration (FDA) has posted a variance amendment submitted by DePaul University's Idea Realization Laboratory. The document is available for review on the Regs.gov platform, with an associated attachment from the Center for Devices and Radiological Health (CDRH).

FDA Variance Approval Letter

The Food and Drug Administration (FDA) has issued a variance approval letter to Laina Callow. The letter, originating from the Center for Devices and Radiological Health (CDRH), indicates a specific approval related to a medical device or process. A redacted version is available for public review.